TEVA - Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
2024-05-09 02:19:50 ET
Summary
- Teva's Q1 earnings show continued momentum, with a 5% increase in total revenue and a jump in gross profit.
- The Company's blockbuster drugs, Austedo and Ajovy, continue to show robust growth and contribute to the company's revenue.
- TEVA's current ratio fell below 1, with debt management challenges and an operating loss from impairment adjustments.
- Teva is a "Hold" due to increased risk and price growth exceeding 50% since December.
Teva's Q1 2024 Earnings Highlight Growth Amid Challenges
Teva's ( TEVA ) stock is up 55% since I called for a "2024 revival" in December. Back then, I was confident that their blockbuster drugs (such as Austedo, Ajovy, and Uzedy) would continue to add value, their capital structure would improve (for example, leverage), and their pipeline would produce results....
Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)